Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
European Urology Focus|February 15, 2021
Liproca Depot: A New Antiandrogen Treatment for Active Surveillance PatientsLaurence Klotz, Stefan Grudén, Niklas Axén, et al.The Journal of Urology|February 19, 2020
Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone AcetateKristina Stuopelyte, Rasa Sabaliauskaite, Arnas Bakavicius, et al.The New England Journal of Medicine|February 15, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.The New England Journal of Medicine|September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with DarolutamideKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5Karim Fizazi, Robert Jones, Stephane Oudard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialFred Saad, Egils Vjaters, Neal Shore, et al.Healthcare (Basel, Switzerland)|November 27, 2021
The Impact of the COVID-19 Pandemic on Cancer Patient's Management-Lithuanian Cancer Center ExperienceDaiva Dabkeviciene, Ieva Vincerzevskiene, Vincas Urbonas, et al.Pageof 5